PAE in the Treatment of Prostate Malignant Tumor

Prostate cancer is one of the most common male genitourinary cancers worldwide. The incidence of prostate cancer varies widely around the world, with the highest region at 150/100,000 and the lowest region at 1/100,000 [1–7]. Of the most common cancers occurred in men, the prostate cancer accounted for almost 1 in 5 new diagnoses [2]. Epidemiologic studies show that prostate cancer is multifactorial and may be related to age, race, genetic background, geographical location, and dietary constituents. Of those, age and family history are the main risk factors, 13% to 26% of prostate cancer patients with positive family history (Table 10.1). Histological study of autopsy showed that approximately 33% of 40–60 years males have prostate cancer [8]. The incidence increases with age and reaches up to 75% in males >85 years [9]. In addition, the incidence in Europe-American males is higher than Asian males, especially, the African American with the highest incident rate. The risk of prostate cancer in Asian males increases when they migrate to Western regions [1, 4].